PMID- 33142121
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jan
TI  - Alpha-1 antitrypsin deficiency and risk of lung cancer: A systematic review.
PG  - 100914
LID - S1936-5233(20)30406-X [pii]
LID - 10.1016/j.tranon.2020.100914 [doi]
LID - 100914
AB  - INTRODUCTION: Alpha-1 antitrypsin deficiency (AATD) is an inherited genetic 
      disorder associated with a risk of developing lung and liver disease. Several 
      studies have examined its possible association with an increased risk of lung 
      cancer. MATERIALS AND METHODS: Systematic review of the scientific literature on 
      studies analyzing the risk of LC associated with AATD, as well as its impact on 
      the histological type and survival. The information was located in the Medline 
      (PubMed), Cochrane, and EMBASE databases. RESULTS: Six studies including a total 
      of 4 038 patients with LC met the inclusion criteria. Most studies included seem 
      to indicate that AATD increases the risk of developing LC, particularly of the 
      squamous and adenocarcinoma types. This risk increases with exposure to tobacco 
      smoke and the diagnosis of chronic obstructive pulmonary disease (COPD). Only one 
      study analyzed the survival of LC patients without finding differences between 
      AATD and non-AATD patients. CONCLUSIONS: These results suggest that AATD may 
      increase the risk of developing LC, particularly of the squamous and 
      adenocarcinoma histological types, but no impact on patient survival has been 
      demonstrated. However, the low quality of the included studies makes it necessary 
      to carry out more studies with a larger sample size and preferably of a 
      prospective nature to confirm these results.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Tubio-Perez, Ramon A
AU  - Tubio-Perez RA
AD  - Pulmonary Department, Hospital Alvaro Cunqueiro, EOXI Vigo; NeumoVigo I+i 
      Research Group, Vigo Biomedical Research Institute (IBIV), Estrada Clara 
      Campoamor,341. 36213. Vigo, Pontevedra, Spain.
FAU - Torres-Duran, Maria
AU  - Torres-Duran M
AD  - Pulmonary Department, Hospital Alvaro Cunqueiro, EOXI Vigo; NeumoVigo I+i 
      Research Group, Vigo Biomedical Research Institute (IBIV), Estrada Clara 
      Campoamor,341. 36213. Vigo, Pontevedra, Spain. Electronic address: 
      maria.luisa.torres.duran@sergas.es.
FAU - Fernandez-Villar, Alberto
AU  - Fernandez-Villar A
AD  - Pulmonary Department, Hospital Alvaro Cunqueiro, EOXI Vigo; NeumoVigo I+i 
      Research Group, Vigo Biomedical Research Institute (IBIV), Estrada Clara 
      Campoamor,341. 36213. Vigo, Pontevedra, Spain.
FAU - Ruano-Ravina, Alberto
AU  - Ruano-Ravina A
AD  - Department of Preventive Medicina and Public Health, University of Santiago de 
      Compostela, Spain, CIBER de Epidemiologia y Salud Publica, CIBERESP, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC7642868
OTO - NOTNLM
OT  - Alpha-1 antitrypsin deficiency
OT  - Histology
OT  - Lung cancer
OT  - Survival
COIS- Declaration of Competing Interest None
EDAT- 2020/11/04 06:00
MHDA- 2020/11/04 06:01
PMCR- 2020/11/01
CRDT- 2020/11/03 20:09
PHST- 2020/08/19 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/11/04 06:01 [medline]
PHST- 2020/11/03 20:09 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - S1936-5233(20)30406-X [pii]
AID - 100914 [pii]
AID - 10.1016/j.tranon.2020.100914 [doi]
PST - ppublish
SO  - Transl Oncol. 2021 Jan;14(1):100914. doi: 10.1016/j.tranon.2020.100914. Epub 2020 
      Nov 1.